The thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple behavioural wager: negative headline shocks tend to be overreactions, and prices drift back toward fundamentals once the noise clears. It buys names hit by a sentiment reading below -0.4 that are also technically oversold — RSI14 under 35 and trading below their 20-day moving average — and sizes into the weakness. Exits come on reversion (RSI14 back above 50, or price reclaiming the SMA20); a hard stop on fresh lows amid continued negativity treats persistent selling as a genuine fundamental break rather than a panic.
The design is grounded in recent sentiment-feedback literature (arXiv:2509.11970, 2025, and corroborating work in JRFM), which is a welcome discipline — the rules trace to a documented asymmetry rather than a curve-fit hunch. The universe is deliberately conservative: 24 mega-cap and large-cap blue chips (AAPL, MSFT, NVDA, JPM, JNJ, XOM, CAT and peers), where overreaction-and-revert dynamics are better behaved than in small caps.
Recent activity
The live book has been busy and short-horizon. Over the last two weeks the strategy round-tripped CAT several times — buying at $621.97 on Nov 3, selling at $585.79 the next day, re-entering at $561.74, exiting again near $559 — and churned NVDA, selling at $177.08 on Nov 9 before buying back at $166.95 on Nov 10. Daily scheduled runs executed one or two trades each with zero rejections, a sign the sanity-banded stops and cash accounting are behaving.
That said, the live equity curve has drifted down, not up: total portfolio value slipped from $9,884 on Nov 3 to $9,599 on Nov 10, sitting below the $10k Season 2 reset line. It is a small sample, but the recent CAT and NVDA entries have so far faded the fader.
Validation and performance
The backtest is the strongest part of the story. Across 1,233 days the strategy returned 37.93% (final equity $13,793), with a 62.88% win rate, a contained 9.3% max drawdown, and a Sharpe of 0.96 over 530 trades. More importantly, walk-forward validation passed cleanly: all four folds were positive, improving fold over fold (1.6% → 3.88% → 10.14% → 21.7%), with the most recent out-of-sample window posting a 2.44 Sharpe. A Probabilistic Sharpe Ratio of 0.985 is excellent.
The risks
Two numbers demand caution. First, the Deflated Sharpe Ratio is only 0.56 — adjusted for 27 trials, the edge is far less certain than the headline PSR suggests, a textbook reminder of multiple-testing inflation. Second, turnover of 5,807% is enormous; the strategy trades constantly, and a 6.79% CAGR, while real, is modest for that activity. In live markets, slippage and the drag of frequent entries could erode a thin edge quickly — exactly what the current sub-$10k live reading may be hinting at. Promising research pedigree and clean folds, but the live tape is the real test, and it is not yet convincing.